Treatment of Newly Diagnosed AML in Fit Patients

Christoph Röllig*, Gert J. Ossenkoppele

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

The diagnosis of acute myeloid leukemia (AML) requires timely treatment in order to avoid life threatening complications. In patients fit for intensive treatment, the realistic goal of treatment is the cure, which can be achieved in around 50% either by cytoreductive treatment alone or in combination with allogeneic stem cell transplantation. Adding novel agents to standard treatment improves its efficacy in certain subgroups. This chapter describes the current treatment standards, how they evolved, discusses concepts of fitness and time frame from diagnosis to treatment, and reveals open questions in conventional treatment as well as future options for first-line treatment with novel agents.
Original languageEnglish
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages199-213
Number of pages15
DOIs
Publication statusPublished - 2021

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Cite this